Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve neurological function and life ability of AIS patients and approved for the treatment of AIS by China Food and Drug Administration (CFDA). Our recent study imply that the neuroprotective effect of DELP involved multiple neuroprotective mechanism such as anti-inflammation, free radical scavenging, and decreasing MMP-9. Based on the multiple mechanisms, DELP was used to investigate the effect on acute ischemic stroke receiving endovascular treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China
Proportion of patients with modified Rankin Score 0 to 2
Time frame: Day 90
Proportion of patients with modified Rankin Score 0 to 1
Time frame: Day 90
Changes in national institutes of health stroke scale (NIHSS)
NIHSS ranges from 0-42, and the decrease in NIHSS means the improvement of neurological deficit.
Time frame: 48 hours
Changes in national institutes of health stroke scale (NIHSS)
NIHSS ranges from 0-42, and the decrease in NIHSS means the improvement of neurological deficit.
Time frame: 7 days
Changes in cerebral infarct volume
Time frame: 48 hours
the occurence of stroke or other cardiovascular events
Time frame: Day 90
the occurence of infections post stroke
Time frame: Day 14
Proportion of symptomatic intracranial hemorrhage (sICH)
sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
Time frame: 48 hours
Proportion of intraparenchymal hemorrhage (PH1 and PH2)
Time frame: 48 hours
the occurence of death due to any cause
Time frame: Day 90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.